No insider purchase over the last 90 days. The latest was filed 03 May 2026.
OCC, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to ASX. In the past year (18 October 2025 to 18 October 2026), 2 filings came from 1 insider.
The flow runs one way only: 1 insider bought (2 purchases totalling €27k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. At €14k, the purchase published on 3 May 2026 is the largest of the period.
The latest purchase dates back some time: it was published 167 days ago, on 3 May 2026.
With 2 filings in twelve months, the company is quieter than the median of 3 filings across the 2,530 companies we follow on the same exchange. Our records for OCC go back to 2026, with 2 purchases and no sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2025 · cache
OCC is a company operating in the healthcare and pharmaceutical sector. It is listed on the XASX market.
Purchases our model currently ranks for the recommendations list.
All recommendations